3-<3',3'-diemthylallyl>-coumaric acid acetate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-<3',3'-diemthylallyl>-coumaric acid acetate
• 英文别名: (2E)-3-[4-(acetyloxy)-3-(3-methylbut-2-en-1-yl)phenyl]prop-2-enoic acid；(E)-3-(4-acetoxy-3-(3-methylbut-2-en-1-yl)phenyl)acrylicacid；(E)-3-prenyl-4-acetoxy cinnamic acid；(E)-3-[4-acetoxy-3-(3-methylbut-2-enyl)phenyl]acrylic acid；4-acetyl-3-prenyl-p-coumaric acid；(E)-3-[4-acetyloxy-3-(3-methylbut-2-enyl)phenyl]prop-2-enoic acid
• 化学式: C₁₆H₁₈O₄
• 分子量: 274.317
• InChiKey: HZLABQIGSINVSS-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-<3',3'-diemthylallyl>-coumaric acid acetate 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (E)-N-(4-hydroxy-3-prenyl cinnamoyl)-L-threonine
  参考文献：
  名称：

  绿蜂胶中青蒿素 C、drupanin 和 baccharin 氨基酸衍生物的合成、抗肿瘤活性和计算机分析

  摘要：

  乳腺癌在女性中的发病率和死亡率最高，而前列腺癌在男性中的发病率第二高。研究表明，巴西绿蜂胶中的化合物具有抗肿瘤活性，可以选择性地抑制在激素依赖性前列腺和乳腺肿瘤中过度表达的 AKR1C3 酶。因此，为了开发针对这些癌症的新细胞毒抑制剂，从绿蜂胶中分离出三种异戊二烯化化合物，青蒿素 C、drupanin 和 baccharin，通过与不同氨基酸的偶联反应合成新的衍生物。所有获得的衍生物都进行了针对四种癌细胞（MCF-7、MDA MB-231、PC-3 和 DU145）和两种正常细胞系（MCF-10A 和 PNT-2）的抗增殖试验，以评估它们的细胞毒性。一般来说，观察到化合物的最佳活性 如图6e所示，衍生自drupanin，其对MCF-7细胞的半数最大抑制浓度(IC 50 )为9.6 ± 3 μM，选择性指数(SI)为5.5。 计算机 研究表明，这些衍生物呈现出针对 AKR1C3 的连贯对接相互作用和结合模式，这可能代表了

  DOI：

  10.1016/j.bmc.2021.116372
• 作为产物：
  描述：

  4-碘-2-(3-甲基-2-丁烯基)-苯酚 在 4-二甲氨基吡啶 、 palladium diacetate 、 silica gel 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 3-<3',3'-diemthylallyl>-coumaric acid acetate
  参考文献：
  名称：

  Potent and Highly Selective Aldo–Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

  摘要：

  Aldo-keto reductase 1C3 (AKR1C3) catalyzes the synthesis of 9 alpha,11 beta-prostaglandin (PG) F-2 alpha and PGF(2 alpha) prostanoids that sustain the growth of myeloid precursors in the bone marrow. The enzyme is overexpressed in acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). Moreover, AKR1C3 confers chemotherapeutic resistance to the anthracyclines: first-line agents for the treatment of leukemias. The highly homologous isoforms AKR1C1 and AKR1C2 inactivate 5 alpha-dihydrotestosterone, and their inhibition would be undesirable. We report herein the identification of AKR1C3 inhibitors that demonstrate exquisite isoform selectivity for AKR1C3 over the other closely related isoforms to the order of >2800-fold. Biological evaluation of our isoform-selective inhibitors revealed a high degree of synergistic drug action in combination with the clinical leukemia therapeutics daunorubicin and cytarabine in in vitro cellular models of AML and primary patient-derived T-ALL cells. Our developed compounds exhibited >100-fold dose reduction index that results in complete resensitization of a daunorubicin-resistant AML cell line to the chemotherapeutic and >100-fold dose reduction of cytarabine in both AML cell lines and primary T-ALL cells.

  DOI：

  10.1021/acs.jmedchem.9b00090

文献信息

• [EN] HIGHLY SELECTIVE AKR1C3 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'AKR1C3 HAUTEMENT SÉLECTIFS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV TEXAS TECH SYSTEM

  公开号：WO2018148721A1

  公开（公告）日：2018-08-16

  The present invention includes methods and compositions that inhibit AKR1C3 enzymatic activity and consequently reduces androgen receptor (AR) transactivation, AR and prostate specific antigen (PSA) expression levels in, for example, prostate cancer, castration-resistant prostate cancer, breast cancer, acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or a leukemia.

  本发明涵盖了抑制AKR1C3酶活性的方法和组合物，从而降低雄激素受体（AR）的转录活性，AR和前列腺特异性抗原（PSA）在例如前列腺癌、去势抵抗性前列腺癌、乳腺癌、急性髓性白血病（AML）、T细胞急性淋巴细胞白血病（T-ALL）或白血病中的表达水平。
• Diterpene glycosides and other constituents from argentinian baccharis species
  作者：C. Zdero、F. Bohlmann、R.M. King、H. Robinson

  DOI：10.1016/s0031-9422(00)83754-1

  日期：1986.1

  investigation of the aerial parts of nine Baccharis species from Argentina gave 37 new compounds, seven ent -clerodanes, 13 ent -labdanes, two friedolabdanes, a nor-labdane ketone, seven coumaric acid derivatives, two umbelliferone derivatives, a flavanone, three sesquiterpenes including a nor-furanocadinene and a propiophenone derivative. Ten of the diterpenes were glycosides. The structures and the configurations

  摘要 对阿根廷 9 种 Baccharis 地上部分的研究得到了 37 个新化合物，7 个 ent-clerodanes，13 个 ent-labdanes，2 个 Friedolabdanes，一个nor-labdane 酮，7 个香豆酸衍生物，2 个伞形酮衍生物，1 个黄烷酮，3 个倍半萜烯包括去甲呋喃卡二烯和苯丙酮衍生物。十种二萜是糖苷。结构和构型由高场核磁共振光谱和一些化学转化确定。二萜的绝对构型是根据观察到的棉花效应提出的，在一种情况下，通过使用霍罗方法和 1 H NMR 确定获得的主要苯基丁酸酯的构型。讨论了化学分类。
• Structure−Antifungal Activity Relationship of Cinnamic Acid Derivatives
  作者：Fabricio Bisogno、Laura Mascoti、Cecilia Sanchez、Francisco Garibotto、Fernando Giannini、Marcela Kurina-Sanz、Ricardo Enriz

  DOI：10.1021/jf0729098

  日期：2007.12.1

  A structure-antifungal activity relationship (SAR) study of 22 related cinnamic acid derivatives was carried out. Attention was focused on the antifungal activities exhibited against Aspergillus flavus, Aspergillus terreus, and Aspergillus niger. (E)-3-(4-Methoxy-3-(3-methylbut-2-enyl)phenyl)acrylic acid (16) exhibited antifungal activity against A. niger, comparable to that of miconazole and a significant antifungal effect against A. flavus and A. terreus as well. A structure-activity relationship (SAR) study of related cinnamic acid derivatives has allowed a model to be proposed for the recognition of the minimal structural requirements for the antifungal effect in this series.
• Synthesis, antitumor activity and in silico analyses of amino acid derivatives of artepillin C, drupanin and baccharin from green propolis
  作者：Débora Munhoz Rodrigues、Gisele Bulhões Portapilla、Guilherme Martins Silva、Andressa Duarte、Cristiana Gonçalez Rotta、Carlos Henrique Tomich de Paula da Silva、Sérgio de Albuquerque、Jairo Kenupp Bastos、Vanessa Leiria Campo

  DOI：10.1016/j.bmc.2021.116372

  日期：2021.10

  have antitumor activities and can selectively inhibit the AKR1C3 enzyme, overexpressed in hormone-dependent prostate and breast tumors. Thus, in an attempt to develop new cytotoxic inhibitors against these cancers, three prenylated compounds, artepillin C, drupanin and baccharin, were isolated from green propolis to synthesize new derivatives via coupling reactions with different amino acids. All obtained

  乳腺癌在女性中的发病率和死亡率最高，而前列腺癌在男性中的发病率第二高。研究表明，巴西绿蜂胶中的化合物具有抗肿瘤活性，可以选择性地抑制在激素依赖性前列腺和乳腺肿瘤中过度表达的 AKR1C3 酶。因此，为了开发针对这些癌症的新细胞毒抑制剂，从绿蜂胶中分离出三种异戊二烯化化合物，青蒿素 C、drupanin 和 baccharin，通过与不同氨基酸的偶联反应合成新的衍生物。所有获得的衍生物都进行了针对四种癌细胞（MCF-7、MDA MB-231、PC-3 和 DU145）和两种正常细胞系（MCF-10A 和 PNT-2）的抗增殖试验，以评估它们的细胞毒性。一般来说，观察到化合物的最佳活性 如图6e所示，衍生自drupanin，其对MCF-7细胞的半数最大抑制浓度(IC 50 )为9.6 ± 3 μM，选择性指数(SI)为5.5。 计算机 研究表明，这些衍生物呈现出针对 AKR1C3 的连贯对接相互作用和结合模式，这可能代表了
• Potent and Highly Selective Aldo–Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
  作者：Kshitij Verma、Tianzhu Zang、Trevor M. Penning、Paul C. Trippier

  DOI：10.1021/acs.jmedchem.9b00090

  日期：2019.4.11

  Aldo-keto reductase 1C3 (AKR1C3) catalyzes the synthesis of 9 alpha,11 beta-prostaglandin (PG) F-2 alpha and PGF(2 alpha) prostanoids that sustain the growth of myeloid precursors in the bone marrow. The enzyme is overexpressed in acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). Moreover, AKR1C3 confers chemotherapeutic resistance to the anthracyclines: first-line agents for the treatment of leukemias. The highly homologous isoforms AKR1C1 and AKR1C2 inactivate 5 alpha-dihydrotestosterone, and their inhibition would be undesirable. We report herein the identification of AKR1C3 inhibitors that demonstrate exquisite isoform selectivity for AKR1C3 over the other closely related isoforms to the order of >2800-fold. Biological evaluation of our isoform-selective inhibitors revealed a high degree of synergistic drug action in combination with the clinical leukemia therapeutics daunorubicin and cytarabine in in vitro cellular models of AML and primary patient-derived T-ALL cells. Our developed compounds exhibited >100-fold dose reduction index that results in complete resensitization of a daunorubicin-resistant AML cell line to the chemotherapeutic and >100-fold dose reduction of cytarabine in both AML cell lines and primary T-ALL cells.